Publication:
Five-year follow-up of drug utilization for secondary prevention in coronary artery disease

Simple item page
dc.contributor.authorSANCAR, MESUT
dc.contributor.authorsRabus, Sule Apikoglu; Izzettin, Fikret V.; Sancar, Mesut; Karakaya, Osman; Kargin, Ramazan; Yakut, Cevat
dc.date.accessioned2022-03-12T17:34:13Z
dc.date.available2022-03-12T17:34:13Z
dc.date.issued2008
dc.description.abstractObjective Despite the availability of various prevention guidelines on coronary artery disease, secondary prevention practice utilizing aspirin, beta-blockers, angiotensin converting enzyme inhibitors and statins still can be sub-optimal. In this study, we aimed to assess the guideline adherence of secondary prevention prescribing and the continuity of adherence for a 5-year period in a small cohort of patients angiographically diagnosed to have coronary artery disease. Method In this prospective study, 73 patients who were angiographically diagnosed to have CAD were followed up for 5 years. The baseline demographic and clinical data were collected just before angiography. The baseline drug data were collected at the day of discharge. The fifth year data were taken from the patients via face-to-face consultations or phone interviews. Results The 'initial prescribing rate' at discharge was found to be 82% for aspirin, 49% for statins, 44% for ACE inhibitors and 55% for beta-blockers. 'Continuity of prescribing' for 5 years was 45% for aspirin, 26% for statins, 17% for ACE inhibitors and 20% for beta-blockers. Conclusions Besides the sub-optimal prescribing of secondary prevention drugs, absence of continuity of prescribing seems to be a challenging issue in pharmaceutical care of coronary artery disease patients.
dc.identifier.doi10.1007/s11096-008-9234-3
dc.identifier.issn0928-1231
dc.identifier.pubmed18563622
dc.identifier.urihttps://hdl.handle.net/11424/228987
dc.identifier.wosWOS:000261036900003
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofPHARMACY WORLD & SCIENCE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDrug Utilisation
dc.subjectFollow up
dc.subjectGuideline
dc.subjectSecondary prevention
dc.subjectCoronary disease
dc.subjectTurkey
dc.subjectACUTE MYOCARDIAL-INFARCTION
dc.subjectCLINICAL-PRACTICE
dc.subjectIMPLEMENTATION
dc.subjectGUIDELINES
dc.subjectMANAGEMENT
dc.subjectDISCHARGE
dc.subjectOUTCOMES
dc.subjectUPDATE
dc.subjectCARE
dc.titleFive-year follow-up of drug utilization for secondary prevention in coronary artery disease
dc.typearticle
dspace.entity.typePublication
local.avesis.id880a316b-4b8c-4171-bf0d-80be3b08e3bd
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
oaire.citation.endPage758
oaire.citation.issue6
oaire.citation.startPage753
oaire.citation.titlePHARMACY WORLD & SCIENCE
oaire.citation.volume30
relation.isAuthorOfPublication87a6fc65-406c-478f-bc6d-ffaaaf1f7b31
relation.isAuthorOfPublication.latestForDiscovery87a6fc65-406c-478f-bc6d-ffaaaf1f7b31

Files

Collections

Research Outputs